Roquinimex (Standard)
Roquinimex (Standard) is the analytical standard of Roquinimex (HY-13743). Roquinimex (Linomide) is an orally active immunomodulator with antineoplastic, anti-inflammatory, and antiangiogenic activity. Roquinimex suppresses TH1 lymphocyte cytokines (IL-2, IFN-γ), promotes TH2 lymphocyte cytokines (IL-4, IL-10), increases NK cell, activated monocyte, and T cell activity. Roquinimex blocks macrophage TNF-α production and suppresses IL-1/IL-6 secretion. Roquinimex exhibits in vivo antitumour activity, suppresses rodent autoimmune disease signs, and ameliorates murine colitis and psoriasis. Roquinimex can be used for the research of leukemia, inflammatory bowel disease, multiple sclerosis, and psoriasis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 98%
- CAS 番号: 84088-42-6
- 分子式: C18H16N2O3
- 分子量:308.33
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
化学情報
- 純度とドキュメンテーション
-
Help & FAQs
-
HY-13743
RoquinimexImmunomodulator -
HY-A0003
LenalidomideImmunomodulator -
HY-15760
Necrostatin-1RIPK1 Inhibitor -
HY-10984
PomalidomideImmunomodulatory Agent -
HY-14622A
Necrostatin 2 racemateRIPK1 Inhibitor -
HY-110203
R-7050TNF Receptor Antagonist -
HY-111255
SPD304TNFα Inhibitor -
HY-108847
EtanerceptTNF Inhibitor -
HY-P9908
AdalimumabTNF-α Inhibitor -
HY-14622
Necrostatin 2RIP kinase Inhibitor -
HY-A0003R
Lenalidomide (Standard)Reference Standard -
HY-N0472
GeraniinTNF Receptor Inhibitor
Product Information
説明
アプリケーション
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
化学情報
-
CAS 番号 84088-42-6
-
分子量 308.33
-
分子式 C18H16N2O3
-
SMILES
O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2)N(C)C3=CC=CC=C3
-
別名
Linomide (Standard); FCF89 (Standard); ABR212616 (Standard)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Ohsuga Y, et al. Dermatologic changes associated with roquinimex immunotherapy after autologous bone marrow transplant. J Am Acad Dermatol. 2000;43(3):437-441. [Content Brief]
[2]. Liu Q, et al. Roquinimex inhibits dextran sodium sulfate-induced murine colitis. Inflamm Res. 2003 Feb;52(2):64-8. [Content Brief]
[3]. Tian WZ, et al. Linomide (roquinimex) affects the balance between pro- and anti-inflammatory cytokines in vitro in multiple sclerosis. Acta Neurol Scand. 1998 Aug;98(2):94-101. [Content Brief]
[4]. Mackean MJ, et al. A feasibility study of roquinimex (Linomide) and alpha interferon in patients with advanced malignant melanoma or renal carcinoma. Br J Cancer. 1998;78(12):1620-1623. [Content Brief]
[5]. Hasan AM, et al. Novel effect of topical Roquinimex and its combination with Clobetasol on an imiquimod-induced model of psoriasis in mice. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(7):5219-5232. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Roquinimex (Standard) 関連分類
HY-13743R 関連分類
Powered by Bioz
Keywords
- Roquinimex (Standard)
- 84088-42-6
- Linomide (Standard)
- FCF89 (Standard)
- ABR212616 (Standard)
- Reference Standards
- TNF Receptor
- Interleukin Related
- IFNAR
- acute myelogenous leukemia
- inflammatory bowel disease
- NK cell
- chronic myelogenous leukemia
- TH1 lymphocyte cytokines
- multiple sclerosis
- advanced renal cell carcinoma
- advanced malignant melanoma
- eccrine sweat gland
- TH2 lymphocyte cytokines
- Inhibitor
- inhibitor
- inhibit